News
08-20-2014, 06:41 AM
Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.
More... (http://www.news-medical.net/news/20140820/Glenmark-announces-discovery-and-initiation-of-IND-enabling-studies-of-innovative-bispecific-antibody.aspx)
More... (http://www.news-medical.net/news/20140820/Glenmark-announces-discovery-and-initiation-of-IND-enabling-studies-of-innovative-bispecific-antibody.aspx)